Phase I of trastuzumab and imatinib mesylate (Gleevec formerly known as STI-571) in patients with recurrent or metastatic HER-2/Neu expressing cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2010
At a glance
- Drugs Imatinib (Primary) ; Trastuzumab
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2006 Status change